Bioelectrical impedance analysis in HIV-infected patients treated with triple antiretroviral treatment

American Journal of Clinical Nutrition

Volumn 70, Issue 5, 1999, Pages 867-873

  Schwenk, Achim ^a   Beisenherz, Alexander ^b   Kremer, Gisela ^b   Diehl, Volker ^b   Salzberger, Bernd ^b   Fätkenheuer, Gerd ^b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

AIDS; Anti HIV agents; BIA; Bioelectrical impedance analysis; Body composition; Body weight; Fat redistribution; Humans; Lipodystrophy; Malnutrition; Protease inhibitors; Triple antiretroviral treatment; Wasting syndrome; Weight loss

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; ARTICLE; BIOENERGY; EXTRACELLULAR FLUID; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPEDANCE; INTRACELLULAR FLUID; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; PREVALENCE; TOTAL BODY WATER;

BIA; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032694298     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/70.5.867     Document Type: Article

References (47)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic milliliter or less. N Engl J Med 1997;337:725-33.
2. Gulick RM, Mellors JW, Havlir D. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
3. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998;280:1497-503.
4. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
5. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-4.
6. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
7. Kotler DP, Burastero S, Wang J, Pierson RN Jr. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: effects of race, sex, and disease. Am J Clin Nutr 1996;64(suppl):489S-97S.
8. Ott M, Fischer H, Polat H, et al. Bioelectrical impedance analysis as a predictor of survival in patients with the human immunodeficiency virus - infection. J Acquir Immune Defic Syndr Hum Retroviral 1995;9:20-5.
9. Schwenk A, Kremer G, Cornely O, Diehl V, Fätkenheuer G, Salzberger B. Body weight changes with protease inhibitor treatment in undernourished HIV-infected patients. Nutrition 1999;15:453-7.
10. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998 ;351:871-5.
11. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998;12:F37-9.
12. Carr A, Samaras K, Burton S. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
13. Kotler DP. Update on lipid abnormalities and cardiovascular complications in HIV infection. World Wide Web: http://www.medscape.com/Medscape/HIV/TreatmentUpdate/1998/tu05/public/toctu05. html (accessed 21 April 1999).
14. Dunbar C, Melahrinides E, Michielli D, Kalinski M. Effects of small errors in electrode placement on body composition assessment by bioelectrical impedance. Res Q Exerc Sport 1994;65:291-4.
15. Moore FD, Oleson KH, McMurray JD, Parker HV, Boyden CM. The body cell mass and its supporting environment: body composition in health and disease. Philadelphia: WB Saunders, 1963.
16. Segal KR, Van Loan M, Fitzgerald PI, Hodgdon JA, Van Itallie TB. Lean body mass estimation by bioelectrical impedance analysis: a four-site cross-validation study. Am J Clin Nutr 1988;47:7-14.
17. Paton NI, Elia M, Jennings G, Ward LC, Griffin GE. Bioelectrical impedance analysis in human immunodeficiency virus-infected patients: comparison of single frequency with multifrequency, spectroscopy and other novel approaches. Nutrition 1998;14:658-66.
18. Data Input. NUTRI4 handbook. Frankfurt, Germany: Data Input GmbH, 1997.
19. Norusis MJ. SPSS advanced statistics, 7.0 update. Chicago: SPSS Inc, 1996.
20. Jeejeebhoy KN. Nutrient requirements and nutrient deficiencies in gastrointestinal diseases. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal disease - pathophysiology/diagnosis/management. 5th ed. Vol 2. Philadelphia: WB Saunders, 1993:2017-47.
21. Souba WW. Drug therapy: nutritional support. N Engl J Med 1997;336:41-8.
22. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41:1-19.
23. Roubenoff R, Roubenoff RA, Preto J, Balke CW. Malnutrition among hospitalized patients. A problem of physician awareness. Arch Intern Med 1987;147:1462-5.
24. Andres R, Elahi D, Tobin JD, Muller DC, Brant L. Impact of age on weight goals. Ann Intern Med 1985;103:1030-3.
25. Shizgal HM. Validation of the measurement of body composition from whole body bioelectrical impedance. Infusionstherapie 1990; 17(suppl):67-74.
26. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA panel. JAMA 1997;277:1962-9.
27. Mulligan K, Tai VW, Schambelan M. Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. J AIDS 1997;15:43-8.
28. Kotler DP, Wang J, Pierson RN. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr 1985;42:1255-65.
29. Rivera S, Briggs W, Qian D, Sattler F. HIV RNA levels correlate with prior weight loss. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, 1998. World Wide Web: http://www.retroconference.org/abs/absset.htm (accessed 21 April 1999) (abstr).
30. Shevitz A, Spiegelman DL, French JK, et al. Increased resting energy expenditure (REE) is associated with increased plasma HIV RNA. 12th World AIDS Conference, Geneva, 1998. World Wide Web: http://www.aids98.ch (accessed 21 April 1999).
31. Carbonnel F, Maslo C, Beaugerie L, et al. Effect of indinavir on HIV-related wasting. AIDS 1998;12:1777-84.
32. Melvin AJ, Mohan KM, Arcuino LA, Edelstein RE, Frenkel LM. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Pediatr Infect Dis J 1997;16: 968-74.
33. Silva M, Skolnik PR, Gorbach SL, et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998;12:1645-51.
34. Mulligan K, Tai VW, Algren H, Chernoff DN, Lo JC, Schambelan M. Evidence of unique metabolic effects of protease inhibitors. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, 1998. World Wide Web: http://www.retroconference.org/abs/abset.htm (accessed 21 April 1999) (abstr).
35. Carr A, Samaras K, Chisholm DJ, Cooper DA. Hypothesis: pathogenesis of HIV-1-protease inhibitor - associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998;352:1881-3.
36. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998;351:867-70.
37. Gervasoni C, Ridolfo AL, Trifirò G, et al. Redistribution of body fat in HIV infected women undergoing combined antiretroviral therapy. AIDS 1999;13:465-71.
38. Foster KR, Lukaski HC. Whole-body impedance - what does it measure? Am J Clin Nutr 1996;64(suppl):388S-96S.
39. Wang J, Kotler DP, Russell M, et al. Body-fat measurement in patients with acquired immunodeficiency syndrome: which method should be used? Am J Clin Nutr 1992;56:963-7.
40. Prior BM, Cureton KJ, Modlesky CM. et al. In vivo validation of whole body composition estimates from dual-energy X-ray absorptiometry. J Appl Physiol 1997;83:623-30.
41. Pietrobelli A, Morini P, Battistini N, Chiumello G, Nunez C, Heymsfield SB. Appendicular skeletal muscle mass: prediction from multiple frequency segmental bioimpedance analysis. Eur J Clin Nutr 1998;52:507-11.
42. Organ L, Bradham G, Gore D, Lozier S. Segmental bioelectrical impedance analysis: theory and application of a new technique. J Appl Physiol 1994;77:98-112.
43. Schambelan M, Mulligan K, Grunfeld C, et al. Serostim Study Group. Recombinant human growth hormone in patients with HIV-associated wasting - a randomized, placebo-controlled trial. Ann Intern Med 1996;125:873-82.
44. Varlet-Marie E, Brun JF, Blachon C, Orsetti A. Relations entre la composition corporelle mesurée par impedancemetrie et la performance motrice sur ergocycle. (Relationships between body composition measured by bioelectrical impedance and exercise performance on cycloergometer.) Sci Sports 1997;12:204-6 (in French).
45. Süttmann U, Ockenga J, Selberg O, Hoogestraat L, Deicher H, Müller M. Incidence and prognostic value of malnutrition in human immunodeficiency virus-infected outpatients. J AIDS 1995;8:239-46.
46. Schwenk A, Ward LC, Elia M, Scott GM. Bioelectrical impedance analysis predicts outcome in patients with suspected bacteremia. Infection 1998;26:277-82.
47. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9.